| Size | Price | |
|---|---|---|
| 1mg | ||
| Other Sizes |
| Targets |
Soladulcoside A is classified as an antineoplastic agent with potential inhibitory activity against cancer cell proliferation . As a steroidal glycoside, its specific molecular targets are not fully elucidated. However, research on structurally related compounds from Solanum nigrum, such as degalactotigonin, has shown significant inhibition of the epidermal growth factor receptor (EGFR) signaling pathway, including suppression of EGFR phosphorylation and downstream activation of Akt and ERK . It is hypothesized that soladulcoside A may exert its effects through similar mechanisms, including the inhibition of the PI3K/Akt pathway and modulation of cell cycle regulators such as cyclin D1 and p21 .
|
|---|---|
| ln Vitro |
Soladulcoside A has demonstrated inhibitory effects on A549 human non-small cell lung cancer cells, suggesting its potential applicability in researching non-small cell lung cancer . In a study evaluating cytotoxic activity against human pancreatic cancer cell lines (PANC1 and MIA-PaCa2) and lung cancer cell lines (A549, NCI-H1975, and NCI-H1299), soladulcoside A showed weak to moderate cytotoxicity, with an IC₅₀ value of 28.4 ± 3.1 μM against A549 cells, while IC₅₀ values against other cell lines (H1975, H1299, PANC1, MIA-PaCa2) were greater than 30 μM . In comparison, a related compound degalactotigonin showed much more potent cytotoxicity (IC₅₀ = 2.9-6.4 μM) . The compound is a steroidal glycoside with antineoplastic properties derived from Solanum nigrum .
|
| Enzyme Assay |
No specific enzyme assay or receptor binding assay protocols for Soladulcoside A are provided in the available search results. However, the compound was isolated and identified from methanolic extracts of Solanum nigrum using various chromatographic techniques, and its chemical structure was elucidated by spectroscopic analyses (including NMR and mass spectrometry) and by comparison with reported data . For research purposes, the compound is soluble in DMSO and can be formulated for in vitro and in vivo experiments using standard protocols, such as dissolution in DMSO followed by dilution with PEG300, Tween 80, and saline .
|
| Cell Assay |
Soladulcoside A was evaluated for cytotoxic activity against human cancer cell lines using the MTT assay . In this assay, cells were seeded in 96-well plates, treated with various concentrations of the compound for 48 hours, and then MTT solution was added. After incubation, formazan crystals were dissolved, and absorbance was measured at 540 nm. The IC₅₀ values were calculated from dose-response curves. Results showed that soladulcoside A exhibited weak cytotoxic activity, with an IC₅₀ of 28.4 ± 3.1 μM against A549 cells, and IC₅₀ values >30 μM against H1975, H1299, PANC1, and MIA-PaCa2 cells . The compound was also tested alongside other steroidal compounds (solasodine, O-acetyl solasodine, and degalactotigonin) isolated from the same plant source . Camptothecin was used as a positive control .
|
| Animal Protocol |
No specific animal experimental protocols for Soladulcoside A are provided in the available search results. However, general in vivo formulation guidelines for this compound include the following example for preparing a working solution: dissolve the compound in DMSO to prepare a mother liquor (e.g., 40 mg/mL), then sequentially add PEG300, Tween 80, and ddH₂O to achieve the desired final concentration . For instance, a formulation of 5% DMSO + 30% PEG300 + 5% Tween 80 + 60% ddH₂O can be used for parenteral administration . These are standard protocols for poorly soluble steroidal saponins and have not been specifically validated for soladulcoside A. All product listings explicitly state that the compound is for research use only and not for human or veterinary use .
|
| ADME/Pharmacokinetics |
As a steroidal glycoside with a molecular weight of 770.9 g/mol and high hydrophilicity due to multiple sugar moieties, the compound is expected to have limited oral bioavailability and is likely metabolized by gut microflora. However, no specific ADME studies for soladulcoside A are reported in the available literature.
|
| Toxicity/Toxicokinetics |
Soladulcoside A is classified as a non-hazardous substance or mixture according to safety data sheets, with no GHS hazard labeling elements required . The compound is not listed as a carcinogen by NTP, IARC Monographs, OSHA, or ACGIH . All product listings explicitly state that the compound is for research use only and not for human or veterinary therapeutic use . No specific toxicological data (LD₅₀, hepatotoxicity, nephrotoxicity) are reported. Recommended storage conditions: powder at -20°C for up to 3 years; in solvent at -80°C for 6 months or -20°C for 1 month, protected from light and moisture .
|
| References | |
| Additional Infomation |
Soladulcoside A (CAS: 137031-53-9) has a molecular formula of C₃₉H₆₂O₁₅ and a molecular weight of 770.9 g/mol . The compound is a white to off-white solid powder . The IUPAC name describes a complex spirostane-type aglycone with a rhamnopyranosyl-(1→2)-glucopyranoside disaccharide unit attached at C-3 . The InChI Key is BVALVRBXQYLPOW-PDVVVGIASA-N . Soladulcoside A was isolated alongside degalactotigonin, solasodine, and O-acetyl solasodine from the methanolic extract of Solanum nigrum, and their chemical structures were elucidated by spectroscopic analyses . While degalactotigonin showed potent cytotoxicity (IC₅₀ = 2.9-6.4 μM) and induced apoptosis and cell cycle arrest via inhibition of EGFR signaling pathways, soladulcoside A exhibited only weak cytotoxic activity (IC₅₀ > 28 μM) . The compound is soluble in DMSO and is typically stored as a powder at -20°C, protected from light . It is shipped at ambient temperature as a non-hazardous chemical .
|
| Molecular Formula |
C39H62O15
|
|---|---|
| Molecular Weight |
770.90
|
| Exact Mass |
770.409
|
| CAS # |
137031-53-9
|
| PubChem CID |
21121519
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.6
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
54
|
| Complexity |
1400
|
| Defined Atom Stereocenter Count |
24
|
| SMILES |
OCC1OC(OC2CCC3(C4CCC5(C6C(C)C7(OC(=O)C(C)CC7O)OC6C(O)C5C4CCC3C2)C)C)C(OC2OC(C)C(O)C(O)C2O)C(O)C1O
|
| InChi Key |
BVALVRBXQYLPOW-JVAKETFISA-N
|
| InChi Code |
InChI=1S/C39H62O15/c1-15-12-23(41)39(54-34(15)48)16(2)24-32(53-39)28(44)25-20-7-6-18-13-19(8-10-37(18,4)21(20)9-11-38(24,25)5)50-36-33(30(46)27(43)22(14-40)51-36)52-35-31(47)29(45)26(42)17(3)49-35/h15-33,35-36,40-47H,6-14H2,1-5H3/t15-,16?,17+,18+,19+,20-,21+,22-,23+,24+,25-,26+,27-,28-,29-,30+,31-,32-,33-,35+,36-,37+,38-,39?/m1/s1
|
| Chemical Name |
(1R,2S,3R,3'R,4R,5'S,8R,9S,12S,13S,16S,18S)-16-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5'-dihydroxy-3',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,6'-oxane]-2'-one
|
| Synonyms |
Soladulcoside A; 137031-53-9; Spirostan-26-one, 3-((2-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-15,23-dihydroxy-, (3beta,5alpha,15alpha,23S,25R)-; RefChem:931944; 3 beta,15 alpha,23 alpha-trihydroxy-5 alpha-spirostan-26-one 3-O-alpha-rhamnopyranosyl-(1-2)-beta-glucopyranoside;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2972 mL | 6.4859 mL | 12.9719 mL | |
| 5 mM | 0.2594 mL | 1.2972 mL | 2.5944 mL | |
| 10 mM | 0.1297 mL | 0.6486 mL | 1.2972 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
